Affinity DataEC50: 1nMAssay Description:Increased percentage of formazan production in drug treated virus infected cells to equal 50% control drug free uninfected cells on serotype 14More data for this Ligand-Target Pair
Affinity DataEC50: 1nMAssay Description:Inhibition of HRV Protease 3CP (serotype 14).More data for this Ligand-Target Pair
Affinity DataEC50: 2nMAssay Description:Inhibition of HRV Protease 3CP (serotype 14).More data for this Ligand-Target Pair
Affinity DataEC50: 3nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype Hanks)More data for this Ligand-Target Pair
Affinity DataEC50: 3nMAssay Description:Inhibition of HRV Protease 3CP (serotype 14).More data for this Ligand-Target Pair
Affinity DataEC50: 3nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 14)More data for this Ligand-Target Pair
Affinity DataEC50: 3nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 11)More data for this Ligand-Target Pair
Affinity DataEC50: 3nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 14)More data for this Ligand-Target Pair
Affinity DataEC50: 4nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 10)More data for this Ligand-Target Pair
Affinity DataEC50: 5nMAssay Description:Increased percentage of formazan production in drug treated virus infected cells to equal 50% control drug free uninfected cells on serotype 14More data for this Ligand-Target Pair
Affinity DataEC50: 5nMAssay Description:Effective concentration against human rhinovirus 3C protease.Checked by AuthorMore data for this Ligand-Target Pair
Affinity DataEC50: 5nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 10)More data for this Ligand-Target Pair
Affinity DataEC50: 6nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 1A)More data for this Ligand-Target Pair
Affinity DataEC50: 6nMAssay Description:Increased percentage of formazan production in drug treated virus infected cells to equal 50% of control drug free uninfected cells on serotype 14More data for this Ligand-Target Pair
Affinity DataEC50: 9nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 19)More data for this Ligand-Target Pair
Affinity DataEC50: 10nMAssay Description:Increased percentage of formazan production in drug treated virus infected cells to equal 50% control drug free uninfected cells on serotype 14More data for this Ligand-Target Pair
Affinity DataEC50: 10nMAssay Description:Increased percentage of formazan production in drug treated virus infected cells to equal 50% control drug free uninfected cells on serotype 14More data for this Ligand-Target Pair
Affinity DataEC50: 10nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 23)More data for this Ligand-Target Pair
Affinity DataEC50: 12nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 78)More data for this Ligand-Target Pair
Affinity DataEC50: 14nMAssay Description:Inhibition of HRV Protease 3CP (serotype 14).More data for this Ligand-Target Pair
Affinity DataEC50: 15nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 1A)More data for this Ligand-Target Pair
Affinity DataEC50: 16nMAssay Description:Inhibition of HRV Protease 3CP (serotype 14).More data for this Ligand-Target Pair
Affinity DataEC50: 20nMAssay Description:Increased percentage of formazan production in drug treated virus infected cells to equal 50% of control drug free uninfected cells on serotype 14More data for this Ligand-Target Pair
Affinity DataEC50: 20nMAssay Description:Increased percentage of formazan production in drug treated virus infected cells to equal 50% of control drug free uninfected cells on serotype 14More data for this Ligand-Target Pair
Affinity DataEC50: 20nMAssay Description:Increased percentage of formazan production in drug treated virus infected cells to equal 50% control drug free uninfected cells on serotype 14More data for this Ligand-Target Pair
Affinity DataEC50: 24nMAssay Description:Inhibition of HRV Protease 3CP (serotype 14).More data for this Ligand-Target Pair
Affinity DataEC50: 30nMAssay Description:Increased percentage of formazan production in drug treated virus infected cells to equal 50% control drug free uninfected cells on serotype 14More data for this Ligand-Target Pair
Affinity DataEC50: 30nMAssay Description:Increased percentage of formazan production in drug treated virus infected cells to equal 50% control drug free uninfected cells on serotype 14More data for this Ligand-Target Pair
Affinity DataEC50: 32nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 10)More data for this Ligand-Target Pair
Affinity DataEC50: 33nMAssay Description:antirhinoviral activity against Human Rhinovirus Protease 3C (serotype 14)More data for this Ligand-Target Pair
Affinity DataEC50: 33nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 3)More data for this Ligand-Target Pair
Affinity DataEC50: 34nMAssay Description:Inhibition of HRV Protease 3CP (serotype 14).More data for this Ligand-Target Pair
Affinity DataEC50: 35nMAssay Description:The EC50 was calculated as the concentration of drug that increased the percentage of formazan production in drug treated,virus infected cells to 50%...More data for this Ligand-Target Pair
Affinity DataEC50: 36nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 16)More data for this Ligand-Target Pair
Affinity DataEC50: 44nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 13)More data for this Ligand-Target Pair
Affinity DataEC50: 44nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 39)More data for this Ligand-Target Pair
Affinity DataEC50: 48nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 2)More data for this Ligand-Target Pair
Affinity DataEC50: 50nMAssay Description:Increased percentage of formazan production in drug treated virus infected cells to equal 50% of control drug free uninfected cells on serotype 14More data for this Ligand-Target Pair
Affinity DataEC50: 50nMAssay Description:Increased percentage of formazan production in drug treated virus infected cells to equal 50% of control drug free uninfected cells on serotype 14More data for this Ligand-Target Pair
Affinity DataEC50: 56nMAssay Description:Effective concentration against human rhinovirus 3C protease.Checked by AuthorMore data for this Ligand-Target Pair
Affinity DataEC50: 58nMAssay Description:Inhibition of HRV Protease 3CP (serotype 14).More data for this Ligand-Target Pair
Affinity DataEC50: 60nMAssay Description:The EC50 was calculated as the concentration of drug that increased the percentage of formazan production in drug treated,virus infected cells to 50%...More data for this Ligand-Target Pair
Affinity DataEC50: 85nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 10)More data for this Ligand-Target Pair
Affinity DataEC50: 100nMAssay Description:The EC50 was calculated as the concentration of drug that increased the percentage of formazan production in drug treated, virus infected cells to 50...More data for this Ligand-Target Pair
Affinity DataEC50: 100nMAssay Description:The EC50 was calculated as the concentration of drug that increased the percentage of formazan production in drug treated, virus infected cells to 50...More data for this Ligand-Target Pair
Affinity DataEC50: 100nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 25)More data for this Ligand-Target Pair
Affinity DataEC50: 104nMAssay Description:Inhibition of HRV Protease 3CP (serotype 14).More data for this Ligand-Target Pair
Affinity DataEC50: 109nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 9)More data for this Ligand-Target Pair
Affinity DataEC50: 111nMAssay Description:antirhinoviral activity against HRV Protease 3CP (serotype 10)More data for this Ligand-Target Pair
Affinity DataEC50: 130nMAssay Description:The EC50 was calculated as the concentration of drug that increased the percentage of formazan production in drug treated, virus infected cells to 50...More data for this Ligand-Target Pair
